Our specialists in Health Economics and Outcomes Research (HEOR)/real-world evidence (RWE), evidence and strategy, market access and policy are eager to discuss your upcoming research priorities and evidence strategy needs.  

 

Join us for our panel discussions:  

What’s Next? Year 1 Learnings of Evidence Planning for IRA Drug Price Negotiation 

• Date and time: Wednesday, May 14, 10:15 – 11:15 AM 

• Moderator: Taylor Schwartz 

• Avalere Health Panelists: Mike Ciarametaro

IRA Under Trump: What Is Next? 

• Date and time: Thursday, May 15, 10:15 – 11:15 AM 

• Moderator: Mike Ciarametaro 

• Avalere Health Panelists: Mike Ciarametaro, Lisa Joldersma 

Navigating Complexities in Calculating Therapeutic Alternative Starting Points in CMS Data 

• Date and time: Friday, May 16, 8:00 – 9:00 AM 

• Moderator: Sarah Moselle 

• Avalere Health Panelists: Jordan Banks, Neil Lund 

 

 

Gain the latest insights from our cross-functional Advisory experts on: 

Using RWE to drive commercial business success: 

• Developing integrated evidence plans that align with access and are responsive to healthcare policy dynamics 

• Supporting manufacturers in navigating a dynamic commercialization environment through curated RWE that articulates asset value to position product for success in long-term and post-launch  

• Assessing patient heterogeneity in the real world to optimize patient identification of high-risk groups, subgroups responding to treatment, and those with barriers to care 

• Evaluating data partnerships to align with manufacturer portfolio evidence requirements 

Improving clinical development and evidence generation strategies to support drug pricing in a post-IRA landscape where foreign reference pricing and tariffs are possible: 

• Advising on early decision making in clinical development cycles given substantial investment in clinical trials 

• Providing unique insights into investment decisions, clinical development programs, and product lifecycle planning in both US and global markets 

• Supporting clients in maximizing evidence applicability and value strategies in response to new policy realities (e.g., IRA Part D Redesign and Negotiation, prescription drug affordability boards, Joint Clinical Assessments) 

• Advising on evidence strategy and generation in preparation for policy changes impacting patient access and reimbursement 

Building a patient-centric value story to move the needle with healthcare decision makers 

• Improving access by creating patient-centric value stories in a way that is relevant to decision makers  

• Navigating methodological challenges in patient-centered data collection to support manufacturers in real-world treatment settings 

• Quantifying the direct and indirect burden patients face and developing patient-centered frameworks 

• Engaging with patients and caregivers to understand their preferences and the indirect burdens of disease 

• Designing and implementing evidence-based interventions and measuring outcomes using implementation science methodologies